Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation
Sponsor: Bausch Health Americas, Inc.
A PHASE3 clinical study on Ulcerative Colitis, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 10 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jun 2019 — Dec 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anaheim, United States, Arlington Heights, United States, Atlanta, United States, Austell, United States, Baltimore, United States, Beverly Hills, United States, Birmingham, United States, Bristol, United States, Brooksville, United States, Charleston, United States and 46 more location s